This is the cold season, and many people are down with runny nose, fever, cough, and tiredness. However, according to experts ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

A panelist discusses how patients should communicate comprehensively with their care team about symptom patterns, documentation methods, and warning signs of polycythemia vera progression, including ...

Actress Susan Sullivan, 82, who announced she was “cancer-free” from non-small cell lung cancer (the most common type of lung cancer) last year, is now battling lymphoma ... at the 2024 American ...

Currently, most treatments for cutaneous T-cell lymphoma do not produce long-lasting benefits, said Timothy Kuzel, MD, '87 '90 GME, clinical professor of Medicine in the Division of Hematology and ...

AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...

Here's what to know about flu symptoms in 2025, how to tell if it's something else, and how to protect yourself: But there are some differences. COVID-19 can show up later than the cold or flu ...

Clinical trials for lymphoma are studies aiming to improve ... What are the signs that lymphoma has progressed to stage 4? The signs and symptoms of stage 4 lymphoma depend on where the cancer ...

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk of disease progression or death by 27% in patients with previously ...